Widely viewed as the largest fast-growing pharma market, China can nevertheless be hard to crack for small to mid-sized companies. But a new policy emphasis on quality and affordability are providing a rare opening for those with the right product mix and local partnerships in hand.
As China rolls out a massive centralized procurement program to slash prices for many widely-used off-patented drugs, some are seeing market opportunities.
Up to now, the generic drug sector in the country - which accounts for over 70% of the world’s second-largest...